Capital International Investors Cellectis S.A. Transaction History

Capital International Investors

$504 Billion
Q3 2024

A detailed history of Capital International Investors transactions in Cellectis S.A. stock. As of the latest transaction made, Capital International Investors holds 1,848,804 shares of CLLS stock, worth $2.88 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,848,804

Previous 1,848,804 -0.0%

Holding current value

$2.88 Million

Previous $3.46 Million 13.36%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$1.83 - $3.84 $2.56 Million - $5.38 Million	1,400,000 Added 311.94%	1,848,804 $3.57 Million
Q3 2022 Nov 14, 2022	SELL	$2.29 - $4.08 $302,813 - $539,510	-132,233 Reduced 22.76%	448,804 $1.03 Million
Q2 2022 Aug 15, 2022	SELL	$2.39 - $4.93 $2.42 Million - $4.98 Million	-1,011,017 Reduced 63.5%	581,037 $1.64 Million
Q4 2021 Feb 14, 2022	BUY	$8.01 - $12.84 $2.02 Million - $3.24 Million	252,718 Added 18.87%	1,592,054 $12.9 Million
Q2 2020 Aug 14, 2020	SELL	$8.21 - $21.02 $541,039 - $1.39 Million	-65,900 Reduced 4.69%	1,339,336 $23.8 Million
Q1 2020 May 15, 2020	BUY	$7.81 - $18.82 $3.04 Million - $7.33 Million	389,300 Added 38.32%	1,405,236 $12.9 Million
Q4 2019 Feb 18, 2020	BUY	$9.73 - $19.31 $2.98 Million - $5.91 Million	306,100 Added 43.12%	1,015,936 $17.4 Million
Q3 2019 Nov 14, 2019	BUY	$10.15 - $16.89 $2.93 Million - $4.88 Million	289,144 Added 68.73%	709,836 $7.38 Million
Q2 2019 Aug 14, 2019	BUY	$14.6 - $20.6 $6.14 Million - $8.67 Million	420,692 New	420,692 $6.56 Million
Q1 2019 May 15, 2019	SELL	$15.53 - $19.75 $3.72 Million - $4.73 Million	-239,391 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$15.58 - $28.41 $3.73 Million - $6.8 Million	239,391 New	239,391 $3.99 Million

Others Institutions Holding CLLS

# of Institutions

Shares Held

10.8M

Call Options Held

5.9K

Put Options Held

1.4K

View Full List

About Cellectis S.A.

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $71M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

More about CLLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Investors with notifications on news.

Account

Capital International Investors Cellectis S.A. Transaction History